Diarrhoea News and Research RSS Feed - Diarrhoea News and Research

Forecast report on Global Ovarian Cancer market

Forecast report on Global Ovarian Cancer market

Research and Markets has announced the addition of the "Global Ovarian Cancer Market 2014-2018" report to their offering. [More]
Simple and hygienic measures can prevent campylobacter infections

Simple and hygienic measures can prevent campylobacter infections

In Switzerland, between 7000 and 8000 persons fall ill with a campylobacter infection annually. This makes it the most frequent bacterial disease transmitted through food. [More]
New estimates highlight the importance of developing norovirus vaccines

New estimates highlight the importance of developing norovirus vaccines

Noroviruses are a leading cause of acute gastroenteritis (diarrhoea and vomiting) across all age groups, responsible for almost a fifth (18%) of all cases worldwide. New estimates, published in The Lancet Infectious Diseases, highlight the importance of developing norovirus vaccines, say the authors. [More]
Noroviruses responsible for almost a fifth of all cases of acute gastroenteritis

Noroviruses responsible for almost a fifth of all cases of acute gastroenteritis

Noroviruses are a leading cause of acute gastroenteritis (diarrhoea and vomiting) across all age groups, responsible for almost a fifth (18%) of all cases worldwide. New estimates, published in The Lancet Infectious Diseases, highlight the importance of developing norovirus vaccines, say the authors. [More]
Adding MM-398 to standard treatment improves survival in metastatic pancreatic cancer patients

Adding MM-398 to standard treatment improves survival in metastatic pancreatic cancer patients

Adding the novel MM-398 to standard treatment for metastatic pancreatic cancer patients who have already received gemcitabine improves survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. [More]
Third-line treatment options remain elusive for advanced, EGFR wild-type NSCLC

Third-line treatment options remain elusive for advanced, EGFR wild-type NSCLC

Phase II study findings show only marginal positive effects of third-line treatment with afatinib for advanced non-small-cell lung cancer in patients with wild-type epidermal growth-factor receptor tumour status. [More]
Review on effects of treating cholera with antimicrobial drugs

Review on effects of treating cholera with antimicrobial drugs

Researchers from the Cochrane Infectious Diseases Group, co-ordinated through the editorial base in LSTM, conducted an independent review of the effects of treating cholera with antimicrobial drugs, published in The Cochrane Library today. [More]
New device designed to detect foodborne bacteria

New device designed to detect foodborne bacteria

A new device designed to sample and detect foodborne bacteria is being trialled by scientists at the University of Southampton. [More]
Molecular mechanism linked to increased risk of diabetes in people with cystic fibrosis

Molecular mechanism linked to increased risk of diabetes in people with cystic fibrosis

Many people with cystic fibrosis develop diabetes. The reasons for this
have been largely unknown, but now researchers at Lund University in Sweden and
 Karolinska institutet have identified a molecular mechanism that contributes to
the raised diabetes risk. [More]
Biótica researchers develop automated laboratory system that rapidly detects E. coli bacterium

Biótica researchers develop automated laboratory system that rapidly detects E. coli bacterium

A Castellón-based biotechnology R&D project by Biótica has been successfully certified by the Centre for Technological and Industrial Development (CDTI, in Spanish), of the Spanish Ministry of Economy and Competitiveness. [More]
Phase III INPULSIS trials show nintedanib slows disease progression in patients with IPF

Phase III INPULSIS trials show nintedanib slows disease progression in patients with IPF

Results from the Phase III INPULSIS™ trials, published online today in the New England Journal of Medicine, show nintedanib significantly slowed disease progression in patients with idiopathic pulmonary fibrosis (IPF). [More]
Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb Company today announced results from a Phase 2 and a Phase 1b study of its investigational PD-1 immune checkpoint inhibitor nivolumab in patients with advanced or metastatic renal cell carcinoma (RCC), commonly known as kidney cancer. [More]
Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb Company today announced updated survival data from the advanced melanoma cohort of Phase 1b study. [More]
Depression is the leading cause of illness in adolescents, shows WHO's report

Depression is the leading cause of illness in adolescents, shows WHO's report

WHO's "Health for the world's adolescents" report reveals that depression is the predominant cause of illness and disability for both boys and girls aged 10 to 19 years. [More]
Zinc supplements reduce diarrhoea and infections in malnourished children

Zinc supplements reduce diarrhoea and infections in malnourished children

Zinc supplements reduce diarrhoea and other infections in malnourished children, and may prevent death, according to a new study published in The Cochrane Library. [More]
Triple therapy shows promise for severe PAH

Triple therapy shows promise for severe PAH

Results of a small pilot study among patients with severe pulmonary arterial hypertension support the long-term benefits of upfront triple combination therapy, French researchers report. [More]
New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1 [More]
New Ebola variant identified in Guinea

New Ebola variant identified in Guinea

Performed in less than a month, sequencing of the complete genome and subsequent phylogenetic analysis show that the virus present in Guinea forms a clade (variant) that is distinct from strains previously identified in the Democratic Republic of Congo and in Gabon. Epidemiological investigations also linked the laboratory confirmed cases with the initial deaths recorded during the December 2013 outbreak. [More]
Ceritinib ‘highly active’ in advanced ALK-rearranged NSCLC

Ceritinib ‘highly active’ in advanced ALK-rearranged NSCLC

Phase I study findings suggest the investigational drug ceritinib is effective in patients with advanced non-small-cell lung cancer with anaplastic lymphoma kinase gene rearrangement, even in those who develop resistance to crizotinib. [More]
Amrubicin regimen inferior to irinotecan for extensive SCLC

Amrubicin regimen inferior to irinotecan for extensive SCLC

Irinotecan plus cisplatin remains the gold standard for Japanese patients with extensive small-cell lung cancer, say researchers, after amrubicin plus cisplatin failed to improve survival in their randomised phase III trial. [More]